Essex Investment Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Essex Investment Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-22,636	Closed	-$1.71M	–	439
2018 Q2	$1.71M	Buy	22,636 +2	+0%	+$126	0.21%	145
2018 Q1	$1.19M	Sell	22,634 -2,301	-9%	-$134K	0.16%	187
2017 Q4	$1.33M	Buy	24,935 +670	+3%	+$37.3K	0.18%	183
2017 Q3	$1.45M	Sell	24,265 -3,096	-11%	-$187K	0.2%	171
2017 Q2	$2.16M	Buy	27,361 +5,367	+24%	+$439K	0.31%	107
2017 Q1	$1.82M	Buy	21,994 +2,391	+12%	+$178K	0.29%	102
2016 Q4	$1.55M	Buy	19,603 +5,082	+35%	+$369K	0.26%	106
2016 Q3	$1.02M	Buy	+14,521	New	+$805K	0.16%	160

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Essex Investment Management's EGRX Position: Q3 2018 in Review

Essex Investment Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2018, closing a stake of 22,636 shares — an estimated $1.71M sold.

Essex Investment Management first reported a position in EGRX in Q3 2016 and held it in 8 quarters. The position peaked at $2.16M in Q2 2017. 189 funds tracked by Wall St. Rank hold EGRX as of Q3 2018.

Essex Investment Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Essex Investment Management sold 22,636 Eagle Pharmaceuticals, Inc. shares in Q3 2018, an estimated $1.71M.
Essex Investment Management first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2016 and held it in 8 quarters.
Essex Investment Management's Eagle Pharmaceuticals, Inc. position peaked at $2.16M in Q2 2017.
189 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2018.

Based on Essex Investment Management's 13F filing for Q3 2018, filed 16 Oct 2018.